Mereo BioPharma (MREO) Income from Continuing Operations (2023 - 2025)
Historic Income from Continuing Operations for Mereo BioPharma (MREO) over the last 3 years, with Q3 2025 value amounting to -$7.0 million.
- Mereo BioPharma's Income from Continuing Operations rose 5317.65% to -$7.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$41.6 million, marking a year-over-year increase of 825.98%. This contributed to the annual value of -$43.3 million for FY2024, which is 4678.95% down from last year.
- Per Mereo BioPharma's latest filing, its Income from Continuing Operations stood at -$7.0 million for Q3 2025, which was up 5317.65% from -$14.6 million recorded in Q2 2025.
- Mereo BioPharma's Income from Continuing Operations' 5-year high stood at -$1.8 million during Q2 2023, with a 5-year trough of -$15.0 million in Q3 2024.
- Its 3-year average for Income from Continuing Operations is -$9.7 million, with a median of -$9.1 million in 2023.
- In the last 5 years, Mereo BioPharma's Income from Continuing Operations plummeted by 59988.58% in 2024 and then skyrocketed by 5317.65% in 2025.
- Quarter analysis of 3 years shows Mereo BioPharma's Income from Continuing Operations stood at -$9.1 million in 2023, then increased by 22.65% to -$7.0 million in 2024, then grew by 0.31% to -$7.0 million in 2025.
- Its Income from Continuing Operations stands at -$7.0 million for Q3 2025, versus -$14.6 million for Q2 2025 and -$12.9 million for Q1 2025.